Flubendiamide and Lead Exposure Alters Glial Fibrillary Acidic Protein and Aspartic Acid Concentrations in Cerebrospinal Fluid in Buffalo Calves

Changes in glial fibrillary acidic protein (GFAP) and aspartic acid (AA) concentrations in CSF following flubendiamide and lead exposure was studied. Male buffalo calves received daily oral dose of flubendiamide alone (n=4) @ 0.024mg/ kg/ day or lead acetate alone (n=4) @ 9.2 mg/ kg/ day or a combination of these two (n=4) for 90 days. Blood and CSF samples were collected and analyzed. GFAP in CSF did not alter in animals receiving flubendiamide alone. However, a significant increase in GFAP concentration in CSF was observed in animals receiving lead acetate. GFAP concentration showed a positive correlation (r = +0.545) with blood lead concentration in lead exposed animals, but no significant correlation was evident in animals exposed to both lead and flubendiamide. On the basis of results, it can be concluded that Aspartic acid concentration in CSF did not change significantly in lead treated animals, but increased significantly in flubendiamide treated animals. No significant alteration in AA level in CSF was observed in combined flubendiamide and lead treated animals. Flubendiamide exposure is associated with increase in AA level in CSF. Flubendiamide may have interactive effects with lead as evident from increase in GFAP and AA level in CSF after their combined exposure. This is the first report documenting alterations in GFAP and AA concentrations in CSF after flubendiamide exposure in mammals.